Top Markets
Coin of the day
TMS Co., Ltd. TMS Co., Ltd.

TMS Co., Ltd.

4891
주식 순위 #27370
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on... Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.
주가
$0.73072946
시가총액
$33.30M
변동 (1일)
0.00%
변동 (1년)
-31.85%
국가
JP
거래 TMS Co., Ltd. (4891)

카테고리

TMS Co., Ltd. (4891)의 EPS
2026 기준 EPS TTM: 0
TMS Co., Ltd.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
TMS Co., Ltd.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH